ZIM
SIOX

Zacks Investment Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Zacks Investment Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-13,700
Closed -$88K – 616
2019
Q3 		$88K Buy
+13,700
New +$94.5K ﹤0.01% 505
2019
Q2 		– Sell
-9,161
Closed -$97K – 632
2019
Q1 		$97K Buy
9,161
+5,485
+149% +$54.6K ﹤0.01% 521
2018
Q4 		$29K Buy
+3,676
New +$53K ﹤0.01% 496
2018
Q1 		– Sell
-3,086
Closed -$130K – 643
2017
Q4 		$130K Buy
+3,086
New +$138K ﹤0.01% 545

Other funds holding SIOX

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EWM
Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Zacks Investment Management's SIOX Position: Q4 2019 in Review

Zacks Investment Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2019, closing a stake of 13,700 shares — an estimated $88K sold.

Zacks Investment Management first reported a position in SIOX in Q4 2017 and held it in 4 quarters. The position peaked at $130K in Q4 2017. 48 funds tracked by Wall St. Rank hold SIOX as of Q4 2019.

  • Zacks Investment Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Zacks Investment Management sold 13,700 Sio Gene Therapies Inc. Common Stock shares in Q4 2019, an estimated $88K.
  • Zacks Investment Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2017 and held it in 4 quarters.
  • Zacks Investment Management's Sio Gene Therapies Inc. Common Stock position peaked at $130K in Q4 2017.
  • 48 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2019.

Based on Zacks Investment Management's 13F filing for Q4 2019, filed 14 Feb 2020.